Physicians and patients may need to become more comfortable with giving up some privacy in exchange for achieving better clinical outcomes, speakers suggested at a Brookings Institution workshop.
Five years from now, the mobile health industry will be much faster-moving and in some ways unrecognizable from today’s field, speakers predicted at a May 22 workshop on mobile technology and health innovation at The Brookings Institution in Washington, D.C.
Workshop moderator Darrell West, vice president and director of governance studies at Brookings, said mHealth is expected to become a $23 billion industry worldwide by 2017.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
